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Abstract
Downstream factors that regulate the decision between senescence and cell death have not been elucidated. Cells undergo
senescence through three pathways, replicative senescence (RS), stress-induced premature senescence (SIPS) and
oncogene-induced senescence. Recent studies suggest that the ataxia telangiectasia mutant (ATM) kinase is not only a key
protein mediating cellular responses to DNA damage, but also regulates cellular senescence induced by telomere end
exposure (in RS) or persistent DNA damage (in SIPS). Here, we show that expression of secretory clusterin (sCLU), a known
pro-survival extracellular chaperone, is transcriptionally up-regulated during both RS and SIPS, but not in oncogene-induced
senescence, consistent with a DNA damage-inducible mechanism. We demonstrate that ATM plays an important role in
insulin-like growth factor 1 (IGF-1) expression, that in turn, regulates downstream sCLU induction during senescence. Loss of
ATM activity, either by genomic mutation (ATM-deficient fibroblasts from an ataxia telangiectasia patient) or by
administration of a chemical inhibitor (AAI, an inhibitor of ATM and ATR), blocks IGF-1-sCLU expression in senescent cells.
Downstream, sCLU induction during senescence is mediated by IGF-1R/MAPK/Egr-1 signaling, identical to its induction after
DNA damage. In contrast, administration of an IGF-1 inhibitor caused apoptosis of senescent cells. Thus, IGF-1 signaling is
required for survival, whereas sCLU appears to protect cells from premature senescence, as IMR-90 cells with sCLU
knockdown undergo senescence faster than control cells. Thus, the ATM-IGF-1-sCLU pathway protects cells from lethality
and suspends senescence.
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Introduction
Senescence has long been considered an important tumor
suppression mechanism. Cellular senescence is a terminal state in
which cells undergo permanent growth arrest accompanied by
morphological changes, e.g., an enlarged and flattened cell shape.
Cells can undergo senescence through three separate pathways
[1,2]: (i) Replicative senescence (RS), induced through shortening
of telomeres as a result of chromosome replication; (ii) Stress
induced-premature senescence (SIPS), induced by cellular stress,
such as elevated oxygen levels or cytotoxic agents causing
extensive DNA damage; and (iii) over-expression or hyper-
activation of oncogenes, such as Ras, c-myc, or BRAF, whose
mechanisms of senescence induction are poorly understood. These
senescence pathways result in cells with uncontrolled oncogene
activation or persistent and extensive DNA damage that perma-
nently arrest growth, and prevent carcinogenesis. While non-
replicative, senescent cells are still metabolically active and express
secretory factors that may significantly alter the cellular microen-
vironment. Characterization of this ‘senescence secretome’ [3],
and more importantly, determining the roles of secretory proteins
in carcinogenesis are areas of active research. Indeed, a few studies
have shown that senescent fibroblasts can promote tumor growth
through certain secreted protein factors [4,5]. Thus, senescence is
most likely beneficial to an organism when cells are young, but a
liability to organs as an organism gets older [6].
Ataxia telangiectasia mutant (ATM) kinase is a major regulator of
certain pathways of senescence. Cells undergoing RS show
telomere shortening due to repetitive replication leading to
uncapped telomeres that can be recognized as DNA double
strand breaks (DSBs) by ATM. Activated ATM can, in turn, signal
downstream effectors. For example, p53 and p21 can mediate
permanent cell cycle arrest [7,8,9,10,11]. In addition, uncapped
telomeres can also activate other DNA damage signaling kinases,
such as ATM-related kinase (ATR) and Ku-dependent DNA
protein kinase (DNA-PK). These kinases play redundant roles in
RS for sensing and responding to the environment, as well as age-
related damage accumulation. Unlike RS, the detailed mecha-
nisms underlying SIPS are less understood. Evidence indicates that
induction of SIPS is also strongly linked to DNA damage
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[10,12,13]. For example, most cell stressors that induce SIPS are
DNA damage-inducing agents, such as growth in elevated oxygen,
exposure to ionizing radiation (IR), and treatment with drugs that
generate DSBs [14,15,16,17,18,19]. All of these agents can
activate ATM, which appears to be an important mediator of
SIPS [15,17]. Nevertheless, factors that regulate the intercellular
decision-making steps of senescence (permanent growth-arrest)
and survival of cells during the senescence process have not been
elucidated.
Secretory clusterin (sCLU) is a stress-inducible, ,80 kDa
secreted glycoprotein implicated in various biological processes
[20], including cellular senescence. Although sCLU over-expres-
sion during cellular senescence has been reported, and sCLU
expression noted as a biomarker of senescence [19,21], the exact
mechanisms regulating its expression during aging have not been
elucidated. One of sCLU’s primary functions is to clear cell debris
from injured cells or tissues, thereby acting as an ‘extracellular
chaperone’ that binds stressed, unfolded proteins for recycling
[22,23]. Additionally, sCLU can protect cells from apoptosis
through its interaction with the pro-apoptotic protein, Bax [22].
sCLU also functions as a tumor promoting factor and is commonly
over-expressed in multiple human cancers, including breast, colon
and prostate. For example, sCLU over-expression has been linked
to increased aggressiveness and metastatic ability in breast cancer
[23,24], and is used as a biomarker to detect triple-negative breast
cancers [25]. Moreover, sCLU over-expression in various cancers
results in resistance to various anti-cancer drugs and ionizing
radiation (IR). Conversely, down-regulation of sCLU by antisense
RNA or small interfering RNA (siRNA) knockdown enhances the
radio2/chemo-sensitivities of human cancer cells [26].
In prior studies, we demonstrated that insulin-like growth factor
1 (IGF-1) induced sCLU via activation of the ATM/IGF-1/IGF-
1R/Src/Erk1-2/Egr-1 pathway in response to DNA damaging
agents, and we showed that sCLU is a sensitive measure of
endogenous and exogenous genomic stress [27,28]. Linking the
known damage-inducible regulation of sCLU with prior reports of
senescence-mediated sCLU over-expression, we hypothesized that
ATM-mediated IGF-1 production during senescence regulated
sCLU expression. Here, we investigated the regulation and
function of sCLU during cellular senescence. We show that sCLU
expression is regulated during senescence through the ATM-
dependent production of IGF-1 during RS and SIPS, but not in
oncogene-induced senescence. IGF-1 expression, in turn, stimu-
lates the Src/MAPK pathway leading to significant sCLU
expression. Importantly, we show that sCLU protects cells from
senescence and that selective siRNA-mediated sCLU knockdown
enhanced progression to senescence. In contrast, preventing IGF-
1-IGF-1R signaling by blocking IGF-1R kinase activity not only
suppressed sCLU expression, but caused significant lethality,
specifically in senescent cells. Our data strongly suggest that the
ATM-IGF-1/IGF-1R-sCLU pathway plays an overall protective
role during senescence, whereby IGF-1 stimulated, IGF-1R
downstream signaling is required for survival and sCLU expres-
sion suspends senescence. We speculate that accumulation of IGF-
1 and sCLU in the media of an aging microenvironment of specific
tissues could contribute to tumor promotion.
Experimental Procedures
Cell Lines and Reagents
IMR-90, BJ, HE49 cells (from Coriell) were cultured in MEM
medium (Invitrogen, Carlsbad, CA, USA), plus 10% FBS, 2 mM
glutamine, 0.5 mM sodium pyruvate. HBEC cells were a gift from
Dr. John Minna (UT Southwestern Medical Center) and cultured
in KSFM medium (Invitrogen) as described [29]. Primary human
ATM-deficient AT fibroblasts, AT2052 and GM03487, were
purchased from Coriell and cultured in MEM medium with 15%
FBS, 2 mM glutamine, 0.5 mM sodium pyruvate. Immortalized
AT fibroblasts [27], with or without restored ATM expression,
were cultured in DMEM medium with 15% FBS, 2 mM
glutamine. All cells were grown with nonessential amino acids.
Antibodies against sCLU (B5), nCLU (H330), total Erk,
phosphorylated Erk, p53 (DO1), b-actin, Egr-1, Src and
phosphorylated Src were from Santa Cruz. Antibodies against
IGF-1 receptor b-chain, phospho-IGF-1 receptor b-chain
(Tyr1135/1136), p16 and p21 were from Cell Signaling. Anti-a-
tubulin antibody was from Calbiochem. IGF-1 receptor inhibitor,
AG1024 was purchased from Sigma. ATM inhibitor, AAI
(CGK733) was purchased from Calbiochem.
An inducible sCLU shRNA plasmid, pTRIPZ-shCLU, was
constructed by sub-cloning the shCLU containing fragment from
pSM2C-shCLUmir vector (Open Biosystem, Lafayette, CO, USA)
into the pTRIPZ empty vector (Open Biosystem). The shCLU
containing fragment was amplified using a pair of primers, 59-
CTTCAGGTTAACCCAACAG-39 and 59-CGAAGT-
GATCTTCCGTCACAA-39 from pSM2C-shCLUmir, and sub-
cloned into the pTRIPZ vector using Xho I and Mlu I. The
resulting plasmid, pTRIPZ-shCLU was sequenced for insert
confirmation. The inducible non-silencing shRNA control plas-
mid, pTRIPZ-nonSilence was purchased from Open Biosystem.
The CLU promoter fused to luciferase was previously described
[28].
Oncogene-induced Senescence
Retrovirus encoding constitutive active RasV12 was transducted
into young IMR-90 cells to induce senescence as described [30].
The same batch of IMR-90 cells was also transducted with
retrovirus alone to serve as control.
Western Blot Analysis
Cells were washed with PBS once, lysed with 50–100 ml lysis
buffer (50 mM Tris pH 6.8, 1% SDS, 10% 2-mercaptoethanol,
16protease inhibitor cocktail (Roche), 16phosphatase inhibitor
cocktail 1 (Sigma), 16phosphatase inhibitor cocktail II (Sigma)).
Protein concentrations were determined by the Bradford Method
and Bio-Rad protein assay dye reagent (Bio-Rad). Western assays
were performed as described [28].
ELISA Assays
IGF-1 was detected using capturing and detecting antibodies,
MAB291 and MAF291 (R&D Systems, Minneapolis, MN, USA)
following the protocol provided by the company. Samples were
normalized to cell number and the total volume of medium.
Senescence-associated b-gal Staining
Cells were washed with PBS, fixed (2% formaldehyde, 0.2%
glutaraldehyde in 16PBS) for 5 mins, and immersed in stain
solution (40 mM Sodium Citrate, pH 6.0, 150 mM NaCl, 5 mM
potassium ferrocyanide, 5 mM potassium ferricyanide, 2 mM
MgCl2, 1 mg/ml X-gal) and incubated overnight at 37uC.
Statistics
Paired Student’s t-tests (n$3) were used to analyze experiments,
which were performed at least three times unless otherwise
specified. Statistics of population doubling curves were calculated
using mixed model analyses by Dr. Jingsheng Yan and Dr. Xian-
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Jian Xie in the Biostatistical Core of the Simmons Comprehensive
Cancer Center, U T Southwestern Medical Center.
Results
Expression of Secretory Clusterin is Transcriptionally
Increased during Senescence
To generate cells at different ages and stimulate stress-induced
premature senescence (SIPS), human normal diploid IMR-90 lung
fibroblasts were continually cultured under 20% O2. Young (Y),
middle-age (M), premature-senescent (PS), senescent (S) and late
senescent (LS) IMR-90 cells were generated over time, as indicated
by decreased population doubling and increased expression of
senescent-associated b-galactosidase-positive (SA-b-gal+) cells
(Figure 1A). Senescence was further confirmed by monitoring
specific biomarkers (i.e., known senescent mediators), including
elevated levels of phosphorylated serine15 p53 (Ser15 p53), total
p53, p21 and p16 proteins (Figure 1B). We also noted a dramatic
Figure 1. sCLU expression is increased during senescence. Young (Y), middle-age (M), premature-senescent (PS), senescent (S), and late
senescent (LS) IMR-90 cells were generated by continuous culture. (A) The ‘‘age’’ of the IMR-90 cells was determined by population doublings and
%SA-b-gal+ cell measurements. Experiments were repeated three or more times in triplicate each, and representative results are shown. (PD,
population doubling). (B) Senescence markers, phospho-ser15-p53, total p53, p21 and p16 levels, were markedly increased during senescence. (C)
Both the precursor (psCLU) and the mature secretory (sCLU) forms of clusterin were induced in total cell lysates during senescence. sCLU levels
increased in the media of senescent IMR-90 cells. (D) The promoter activity of sCLU was increased during senescence. *, p-value#0.05, **, p-value#
0.01.
doi:10.1371/journal.pone.0099983.g001
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Figure 2. sCLU expression is differently regulated in SIPS, RS and oncogene-induced senescence. (A) sCLU levels were increased during
senescence in BJ, HE45 and HBEC cells. BJ, HE45 and HBEC cells were aged by continuous cell culture and senescence status determined by %SA-b-
gal+ cells. (B) Forced expression of Ras12V represses sCLU expression. Young IMR-90 cells were transduced with lentiviral-mediated Ras12V
expression. After cells exhibited typical senescence morphology, stained SA-b-gal+, and were growth arrested, they were harvested and sCLU levels
monitored by Western blotting. Phospho-Erk-1/2 was probed to monitor the effects of Ras12V over-expression. a-Tubulin was used for a loading
sCLU Regulation and Its Role in Senescence
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increase in pre-mature (,60 kDa psCLU) and mature (,40 kDa
sCLU) forms of clusterin (a.k.a. apolipoprotein J) protein during
senescence (Figure 1C); mature sCLU is ,80 kDa formed by
dimerization of two ,30 kDa a and b sCLU peptides that are
heavily glycosylated, but appear as ,40 kDa forms under SDS
reducing conditions. Both psCLU and sCLU protein forms were
concomitantly increased in middle-aged IMR-90 cells, and
expression of both protein forms were further increased in
premature-senescent (PS) cells, with peak levels demonstrated in
senescent (S) IMR-90 cells. Mature sCLU levels were also found
dramatically increased in the ‘conditioned’ media of middle-aged
and senescent fibroblasts (Figure 1C). To explore whether CLU
up-regulation was controlled at the transcriptional level, a human
4280 bp CLU promoter-luciferase reporter (hCLUp-Luc) was
used. hCLUp-Luc activity was increased 2-fold in middle-aged
IMR-90 cells compared to young cells, while 4-fold increased
promoter activity was observed in senescent IMR-90 cells
(Figure 1D). Overall, these data strongly suggested that sCLU
protein expression was transcriptionally up-regulated in IMR-90
cells during SIPS.
sCLU is Induced in Cells Undergoing RS or SIPS
To investigate whether sCLU expression increases were specific
to cells undergoing SIPS, we examined other normal human
diploid cells, BJ, HE49 and human bronchial epithelial cells
(HBECs), that undergo RS, and are not subject to SIPS under the
relatively elevated O2 levels found under normal tissue culture
growth conditions. In all three cells, psCLU and sCLU levels were
increased in cells undergoing RS (Figure 2A). Thus, sCLU levels
are enhanced by both RS and SIPS.
IMR-90 cells are hypersensitive, and significantly growth-
arrested, by elevated O2 levels in cell culture [31]. IMR-90 cells
underwent senescence much more rapidly when cultured in 20%
O2 compared to cells cultured under 2% O2, as indicated by
decreased population doubling times and dramatically increased
levels of SA-b-gal+ cells (Figure 2C). In contrast, BJ cells are not
particularly sensitive to oxygen (O2) and no significant difference
in their population doubling times were noted in cells cultured
under 20% versus 2% O2 (Figure 2D). Thus, BJ cells primarily
undergo RS regardless of O2 levels, and sCLU induction responses
were identical (as shown in Figure 2A) in these cells regardless of
O2 levels.
To investigate the effect of O2 levels on sCLU expression during
SIPS versus RS in IMR-90 cells, we examined psCLU and sCLU
steady state levels in IMR-90 cells cultured under 20% or 2% O2
growth conditions. sCLU levels were significantly elevated in
IMR-90 cells cultured under 20% O2 at passages (13–21) where
cells were undergoing SIPS, compared to identical cells cultured in
2% O2 (Figure 2E), in which no significant senescence was noted
(Figure 2C). Thus, sCLU expression correlated well with SIPS in
IMR-90 cells. Finally, we examined cells undergoing oncogene-
induced senescence by transfecting constitutive-active Ras12V into
young IMR-90 cells, a method commonly used to induce
oncogene-stimulated senescence [30]. Interestingly, basal sCLU
expression was repressed in Ras12V-expressed young IMR-90
cells (Figure 2B). These results are consistent with prior findings
suggesting that Ras over-expression negatively regulates sCLU
expression [32], and strongly suggests that sCLU is not induced
during oncogene-induced senescence.
Prior research from our laboratory demonstrated that sCLU
induction in response to DNA damaging agents, such as ionizing
radiation (IR), occurred through IGF-1 production, stimulating
IGF-1R/MAPK/Erk-1/2 signaling, culminating in activated Egr-
1 that transcriptionally regulated sCLU expression [28]. We
previously demonstrated that such responses were mediated by
ATM activation, and not through ATR [27]. Since both RS and
SIPS activate ATM via cellular DNA damage responses (DDR),
we treated young (P13, PD#17), middle-aged (P18, PD#36) and
senescent (P21, PD#92) IMR-90 cells with IR, then examined
sCLU expression. sCLU levels were dramatically increased in
young cells in response to IR treatment, while no additionally
increases in sCLU levels were noted in irradiated senescent IMR-
90 cells, which expressed extremely elevated basal levels of this
pro-survival protein compared to young IMR-90 cells (Figure 2F).
These results indicated that senescence-induced sCLU might
employ the same signaling pathway as DDR-induced sCLU [27].
Consistent with this pathway, we noted that Erk-1 was activated
(increased p-Erk-1/t-Erk) during senescence (Figures 2E and 2F),
and activation of Erk-1 was further induced after IR treatment in
young (Y) or middle-aged (M) IMR-90 cells. In contrast, IR
exposure of senescent (S) IMR-90 cells caused no further Erk-1
activation (Figure 2F). Thus, the signaling pathway required for
sCLU expression was already saturated in senescent IMR-90 cells.
These results again strongly suggested that senescence-induced
sCLU expression is mediated through the same signaling pathway
as DDR-induced sCLU expression noted in Goetz et al. [27].
ATM Mediates IGF-1-sCLU Expression during Senescence
ATM plays a central role in DDRs, as well as cellular
senescence through RS or SIPS, to signal downstream effectors
controlling survival and cell death [10]. To test whether ATM
regulated sCLU expression during cellular senescence, we aged
human diploid Ataxia telangiectasia (AT) patient (AT2052) fibroblasts
that lack functional ATM expression. AT2052 cells expressed
significantly lower basal level expression of sCLU compared to
wild-type ATM+ IMR-90 cells. These data are consistent with
prior data from our lab, where ATM controlled IGF-1-sCLU
expression after DNA damaging agents, and low basal levels of
sCLU noted in AT cells were noted as resulting from detectable
IGF-1 in the growth medium [27]. As expected, sCLU was not
induced in senescent AT2052 versus IMR-90 cells (Figure 3A).
Furthermore, AT cells were capable of inducing sCLU, since
exposure of AT2052 cells with IGF-1 resulted in significant sCLU
expression in 24 h compared to untreated control cells, and sCLU
levels remain elevated 72 h after IGF-1 exposure (Figure 3B).
Accordingly, activated Erk (increased P-Erk/t-Erk) was concom-
itantly noted 24 h after IGF-1 treatment (Figure 3B). These results
indicated that signaling from IGF-1/IGF-1R to sCLU was still
intact in ATM-deficient AT2052 cells. To further confirm this
finding, another AT cell line (GM03487) was treated with IGF-1,
and similarly, sCLU expression was increased in GM03487 cells
24 h post-treatment (Figure 3B). Similar results were also observed
control. (C) IMR-90 cells cultured in 20% oxygen (O2) underwent senescence faster than cells cultured in 2% O2. The population doubling of IMR-90
cells cultured in 20% O2 decreased faster than cells cultured in 2% O2. (D) BJ cells were not affected by different O2 tensions. In contrast to IMR-90
cells, the population doublings of BJ cells were identical whether cultured in 20% or 2% O2. (E) sCLU levels increased in IMR-90 cells cultured in 20%
O2 compared to levels found in IMR-90 cells cultured in 2% O2 in both early and late passage cells. (F) Young (Y), middle-aged (M), and senescent (S)
IMR-90 cells were treated with IR (10 Gy). psCLU, sCLU, total Erk-1/2 (Erk) and phosphorylated Erk-1/2 (pErk) were detected by western blot analyses.
For (C) and (D), representative results are presented from at least three repeat experiments with similar results.
doi:10.1371/journal.pone.0099983.g002
sCLU Regulation and Its Role in Senescence
PLOS ONE | www.plosone.org 5 June 2014 | Volume 9 | Issue 6 | e99983
Figure 3. ATM is required for sCLU induction during senescence. (A) ATM-deficient AT cells have extremely low basal sCLU levels, where
expression is regulated purely by IGF-1 in the medium [27]. sCLU levels were increased in both total lysates and in the medium from senescent IMR-
90 cells, however, sCLU was not changed during senescence in AT2052 cells. The %SA-b-gal+ cells in the population from young IMR-90 cells was ,
5%, whereas the percentage of senescent IMR-90 cells was.60%. The %SA-b-gal+ cells in the Young AT2052 cell population was,20%, whereas the
senescent population was .60% for AT2052 cells. (B) IGF-1 induced sCLU in ATM-deficient, AT fibroblasts. ATM-deficient AT2052 or GM03487 cells
were cultured in 0.2% FBS medium overnight, and then treated with IGF-1 (10 ng/ml). Cells were harvested at the indicated times and sCLU as well as
total and phospho-Erk-1/2 levels were measured by Western Blotting from total cell lysates. a-Tubulin levels were used for loading. (C) IGF-1 induces
sCLU in genetically matched ATM-deficient and -proficient AT cells. Immortalized AT cells (AT2/2) and wild type, ATM reconstituted cells (ATM+)
were cultured in 0.2% FBS medium overnight. IGF-1 (10 ng/ml) was then added in both ATM+ and ATM2/2 cells. Cells were harvested at indicated
times and sCLU and a-tubulin levels were monitored as described above. (D) Inhibition of ATM activity represses sCLU expression in senescent IMR-90
cells. psCLU and sCLU were repressed by the ATM inhibitor, AAI, in both total cell lysates and medium from senescent IMR-90 cells (%SA-b-gal+ were
.60%). These cells were pre-cultured in 0.2% FBS medium overnight, then treated with 1.0 or 2.5 mM AAI or exposed to vehicle alone. After
treatment (48 h), cells and medium were collected and Western Blot analyses were performed to measure sCLU level. a-Tubulin levels were used to
monitor loading. (E) Inhibition of ATM activity repressed IGF-1 expression in senescent IMR-90 cells. IGF-1 levels in the media from cells in (D) were
measured using ELISAs as described in ‘Materials and Methods’. Human recombinant IGF-1 was used as standard. Results were normalized to both
total volume of medium and total cell number.
doi:10.1371/journal.pone.0099983.g003
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using a pair of immortalized AT cells lacking or reconstituted with
ATM (Figure 3C), as demonstrated in Goetz et al., [27].
Collectively, these data are consistent with an ATM-mediated,
IGF-1-regulated sCLU expression pathway that signals through
the IGF-1 receptor (IGF-1R)/MAPK/Erk-1/2/Egr-1 signaling
pathway. The low level of constitutive sCLU expression, and lack
of induction of sCLU during senescence in AT cells is due to the
lack of functional ATM and not due to signaling from IGF-1/IGF-
1R to sCLU expression. These data are consistent with the
hypothesis that ATM controls IGF-1 expression during senes-
cence, as it does after DDRs [27].
To further demonstrate a role for ATM in sCLU expression in
senescent IMR-90 cells, the ATM and ATR inhibitor (AAI in
0.2% FBS medium) was used to decrease intracellular psCLU and
sCLU expression, as well as mature sCLU expression in
conditioned medium (Figure 3D). We further analyzed IGF-1
levels in the medium and found that inhibition of ATM
significantly decreased IGF-1 expression in these cells (Figure 3E).
Taken together, these results suggested that ATM was an
important mediator of sCLU expression during senescence, where
it regulates sCLU expression by controlling IGF-1 levels.
sCLU Induction during Senescence is Mediated by IGF-
1R/MAPK/Erk-1/2/Egr-1 Signaling
Our data strongly suggested that functional ATM could
regulate IGF-1 expression during RS or SIPS pathways. Indeed,
IGF-1 expression was approximately two-fold higher in condi-
tioned media from senescent compared to young IMR-90 cells
(Figure 4A). Analyses of differential signal transduction responses
in senescent versus young IMR-90 cells showed that IGF-1
Figure 4. sCLU induction during senescence is mediated through IGF-1R/MAPK/Erk/Egr-1 signaling pathway. (A) IGF-1 expression was
increased in senescent IMR-90 cells. IGF-1 levels in media from young or senescent IMR-90 cells were measured using ELISAs as described above, and
normalized to media volume and adjusted cell number (46104 cells). (B) Total IGF-1 receptor (IGF-1R), phosphorylated IGF-1 receptor (p-IGF-1R), Src,
phosphorylated Src, Erk-1/2, phosphorylated-Erk-1/2, and Egr-1 levels in young (Y), middle-age (M), premature-senescent (PS), and senescent (S) IMR-
90 cells were determined by western blot analyses. b-Actin levels were measured to monitor loading. (C) Exposure to the indicated doses of the IGF-
1R tyrosine kinase inhibitor (AG1024) repressed sCLU levels in senescent IMR-90 cells. psCLU and sCLU were detected by western blot analysis. b-
Actin levels were monitored to show equal loading. Senescent IMR-90 cells exposed to varying doses of AG1024 (mM as indicated for 24 h) showed
dose-dependent increases in apoptosis (monitored by TUNEL + staining). Only senescent, and not young or middle-aged IMR-90, cells were
hypersensitive to AG1024. In the experiment outlined below the western blot analyses cells were exposed to AG1024 (5 mM) for 48 h and therefore
higher levels of apoptotic cells were noted in senescent IMR-90 cells compared to cells exposed for 24 h above. Note that only senescent cells were
hypersensitive to these inhibitor treatments. All experiments were repeated three times in triplicate.
doi:10.1371/journal.pone.0099983.g004
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Figure 5. sCLU protects cells from senescence. (A) sCLU was knocked down in an IMR-90 pooled population containing a lentiviral-mediated
inducible shRNA-sCLU construct cultured in presence of doxycycline (dox), while expression of sCLU was not affect in the same pooled population in
the absence of doxycycline (dox). The population doubling of IMR-90 cells with inducible shRNA-sCLU decreased faster when cultured in the
presence of dox compared to in cells cultured without dox. **, p-value of two curves was #0.01. Experiments were repeated three times, starting
from infection of young IMR-90 cells with selection of a pTRIPZ-shCLU-containing pooled population. Similar results were observed in all three
experiments and representative results from one experiment are shown. (B) IMR-90 cells with sCLU knockdown had significantly higher %SA-b-gal+
cells after being cultured for 33, 39, and 53 days with or without dox. SA-b-gal+ staining was performed to identify senescent cells. *, p-value #0.05.
(C) Controls included a pooled IMR-90 cell population contain an inducible shRNA-non-targeted, scrambled shRNA construct were cultured in
sCLU Regulation and Its Role in Senescence
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receptor (IGF-1R) levels were activated (elevated P-IGF-1R/t-
IGF-1R) in senescent cells; antibodies to human IGF-1R are not
ideal. Src and Erk-1/2 kinase levels were also elevated in middle-
aged and senescent compared to young IMR-90 cells. The
transcription factor, Egr-1, which binds the hCLU promoter and
mediates sCLU expression [28], was significantly increased during
senescence in IMR-90 cells (Figure 4B). To further confirm the
specificity of IGF-1/IGF-1R/MAPK/ERK-1/2/Egr-1 signaling
in sCLU induction during senescence, we treated senescent IMR-
90 cells with the IGF-1R inhibitor, AG1024, which effectively
blocked IR-induced sCLU expression [27,28] and also suppressed
sCLU expression in senescent IMR-90 cells in a dose-dependent
manner (Figure 4C). While significantly suppressing sCLU
expression, we also noted that senescent IMR-90 cells exposed
to the IGF-1R inhibitor (AG1024) underwent significant pro-
grammed cell death (apoptotic) responses in a dose-dependent
manner (Figure 4C). Interestingly, young and middle-aged cells
did not respond to AG1024 in the same manner with no
significant apoptosis noted after exposure to 5 mM of the drug
(Figure 4C). Collectively, these results strongly suggest that when
cell undergo RS or SIPS, but not oncogene-induced senescence,
ATM-dependent DDR leads to increased IGF-1 expression that
stimulates IGF-1R/MAPK/Erk-1/2/Egr-1 signaling that leads to
concomitant elevated sCLU levels. The data further suggest that
the IGF-1/IGF-1R-sCLU pathway is required for the overall
survival of senescent cells, whereby suppressing this pathway
induces an intracellular death decision.
sCLU Knockdown Promotes Cellular Senescence
sCLU functions as an extracellular chaperone, protecting cells
from inflammation, and suppressing apoptosis by its proposed
interaction with Bax [22,33]. Its role in senescence has not been
defined. Given the increased apoptotic responses in cells deficient
of sCLU expression (Figure 4C) exposed to an IGF-1R inhibitor,
we theorized that the effects of the IGF-1R inhibitor were due to
the proposed apoptotic inhibitory effects of psCLU/sCLU. To
explore sCLU’s role in senescence, we generated a conditionally
inducible, doxycycline-regulated shRNA-sCLU knockdown lenti-
viral expression vector, pTRIPZ-shCLU. When infected into cells,
pTRIPZ-shCLU controlled expression of shRNA specific to the
intron I/Intron III junction found only in sCLU mRNA, and not
in nuclear clusterin (nCLU) mRNA (Figure 5E); nCLU is a
cytosolic form of clusterin that induces cell death when activated
and translocated to the nucleus [35,36]. Early passage IMR-90
cells were first transduced with lentiviral pTRIPZ-shCLU, then
selected with puromycin to generate a pooled population.
pTRIPZ-shCLU-containing IMR-90 cells were then cultured
with or without Dox, and population doublings (PDs) and %SA-b-
gal+ cells monitored over time. Interestingly, Dox-treated,
pTRIPZ-shCLU-containing IMR-90 cells with continuous sCLU
knockdown showed decreased population doublings at ,passage
20 (Figure 5A), suggesting that loss of sCLU expression enhanced
SIPS responses in IMR-90 cells. Significant population doubling
time differences were noted (p-value of two population doubling
curves = 0.0001), with control cells plateauing at ,40 days in
culture, while Dox-treated IMR-90 cells underwent senescence at
day 32 (Figure 5A). Enhanced senescence was confirmed by
significant differences in the %SA-b-gal+ cells, where at least two-
fold increases were noted compared to untreated pTRIPZ-shCLU
IMR-90 cells that expressed sCLU at day 39 (Figure 5B). sCLU-
shRNA knockdown was confirmed in Dox-exposed pTRIPZ-
shCLU IMR-90 cells by Western blotting, while sCLU levels in
cells similarly cultured without Dox were not affected and were
significantly elevated (Figure 5A). To verify that these results were
not affected by addition of Dox or lentiviral infection alone, we
generated pooled clones using the same vector, but contain a non-
targeting shRNA (pTRIPZ-non silencing). As shown in Figures 5C
and 5D, Dox-inducible non-silencing shRNA had no affect on
sCLU expression (Figure 5C), both population doubling times and
%SA-b-gal+ cells were not significantly different with or without
Dox exposure over the life of the IMR-90 cultures (Figure 5C).
These results strongly suggested that decreased sCLU expression
due specifically to shRNA-sCLU knockdown, facilitated senes-
cence in IMR-90 cells. Thus, sCLU appears to play a protective
role from senescence in IMR-90 cells. Interestingly, however, loss
of sCLU did not lead to significant induction of apoptosis, strongly
suggesting that the role of sCLU in senescence is to suspend the
process and not to keep these cells alive. These data also strongly
suggest that IGF-1/IGF-1R signaling, in contrast, is a major
contributing factor that protects against programmed cell death
induction in cells.
Discussion
Here, we show that sCLU is up-regulated at a transcription level
during both RS and SIPS, but is not elevated in response to
oncogene-induced senescence. This is consistent with prior
findings in the literature showing that sCLU was induced in WI-
38 cells during RS or after H2O2-induced SIPS [19,21].
Mechanistically, we also demonstrated that sCLU was induced
during senescence through the ATM/IGF-1/IGF-1R/MAPK/
Erk-1/2/Egr-1 signaling pathway, a pathway that is also
stimulated and regulates sCLU induction during DDR (Figure 6).
These results support the observation that cellular senescence
processes share significant overlap with DDR pathways. And
many key factors (e.g., ATM, p53, p21) that are involved in the
DDR in human cells also play important roles in cellular
senescence responses.
Importantly, our data clearly support a role for ATM in the
induction of sCLU levels in senescent cells by controlling IGF-1
expression. Upon DNA damage, including uncapped telomere
ends of extensive DNA lesions created in SIPS responses, ATM is
recruited to the damage site and activated via phosphorylation
[34]. Activated ATM, in turn, stimulates several proteins that can
mediate DNA damage repair, cause transient growth arrest, and
possibly lead to cell death or senescence. Ironically, loss of ATM
function sensitizes cells to DNA damage, leading to enhanced cell
death and possibly senescence. ATM can be activated by naked
telomeres and trigger cellular senescence signaling during RS
[7,11,35]. Similarly, ATM activation by overwhelming DSB
presence or absence of dox. Growth rates and sCLU levels were not affected in the shRNA-Scr (non-targeted) IMR-90 cell populations. Population
doubling of IMR-90 cells with inducible non-targeting shRNA was not different when cultured with/without doxycycline. The experiments were
repeated three times similarly as inducible shCLU experiments. Representative results of three experiments were shown here. (D) After culturing for
38, 45, and 65 days with or without dox, SA-b-gal+ staining was performed to identify senescent cells in IMR-90 pooled populations with inducible
shRNA-Scr (non-targeting) vector. (E) Specificity of shCLU knockdown in conditional IMR-90 senescent cells. IMR-90 pooled populations containing
the pTRIPZ-shCLU vector was cultured with or without doxcycline (100 nM for 3 days) and sCLU and nCLU levels were monitored using Western blot
analyses. a-Tubulin levels were shown as a loading control. Note that sCLU and not nCLU levels were specifically knocked down (.90%) in cells
exposed to dox. In these experiments, IMR-90 cells were cultured in 95% air-5% CO2, estimated at ,20% O2.
doi:10.1371/journal.pone.0099983.g005
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lesions may also lead to senescence signaling during SIPS.
However, ATM also plays a protective role in aging and cellular
senescence, since ATM-deficient AT cells undergo senescence
faster [38,39,40]. Consistently, AT patients also age faster. Our
finding that ATM up-regulates and controls the IGF-1-sCLU
expression axis [27], as well as sCLU protecting cells from
senescence, may help to explain the role of ATM in senescence/
aging protection (Figure 6).
Our results demonstrate that sCLU protects cells from
senescence, suggesting that a role of increased sCLU expression
in senescent cells is to counteract senescence by some as yet known
mechanism. This result is consistent with the role of ATM in
protecting cells from senescence. AT fibroblasts expressed low
basal levels of sCLU, and failed to induce sCLU during senescence
or DDR responses, due to the lack of ATM signaling (Figure 3A)
that controls IGF-1 production [27]. Thus, the role of sCLU
expression in DDR responses mirrors ATM, as both AT cells and
cells knocked down for sCLU expression are hypersensitive to
oxidative stress and senescence. AT patients also age faster
[38,39,40], and patients with lowered circulatory sCLU levels also
age less well than Centenarians in a recent study [36]. Re-
introduction of ATM into AT cells increased the lifespan of AT
cells and restored sCLU induction responses after DDR or
senescence induction pathways [27]. Collectively, these results
suggest that sCLU may play a role(s) in aging. Furthermore,
increased levels of sCLU may protect cells from senescence
(Figure 6).
Our original hypothesis was that as an anti-apoptotic protein,
sCLU may increase the population doubling by protecting cells
from spontaneous apoptosis. However, when sCLU was knocked
down in middle-aged or senescent IMR-90 cells, we did not
observe an increase in apoptosis in this cell population. These data
suggest that the anti-apoptotic function of sCLU may somehow
not be operative during senescence and may not contribute to
increased cell growth. Surprisingly, Dox-induced shRNA-sCLU
knockdown IMR-90 cells showed increased SA-b-gal+ stained
cells, confirming its role in senescence protection (Figure 5). sCLU
also functions as an extracellular chaperone, that helps clear
unfolded proteins from the surrounding microenvironment
(conditioned medium). Several studies have shown that other
chaperones, like heat shock proteins (HSPs), were involved in
cellular senescence [37,38,39,40,41]. Decreasing or inhibiting
Hsp90 or Hsp72 induced cellular senescence, while over-
expression of Hsp72 suppressed senescence pathways [37,38,39].
A small heat shock protein, Hsp27, also suppressed senescence by
modulating p53 signaling [40]. Thus, sCLU may protect cells from
senescence by decreasing cellular stress caused by the accumula-
tion of denatured proteins, since both the cellular level of HSPs
and protein quality control declines during senescence [41].
Furthermore, other findings, as well as our results have shown that
extracellular sCLU can interact with several cell surface receptors,
Figure 6. A model of the signaling pathway that mediates sCLU induction during senescence showing the role of sCLU in
senescence compared to IGF-1/IGF-1R signaling required to prevent apoptosis. AAI and AG1024 are small molecule chemical inhibitors
that inhibit ATM and ATR, and IGF-1 tyrosine kinase receptor (IGF-1R), respectively.
doi:10.1371/journal.pone.0099983.g006
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such as IGF-1R, TGF-b receptor I and TGF-b receptor II, and its
interactions with these receptors modulates their activities in as yet
undefined mechanisms. Both IGF-1 and TGF-b receptor-mediat-
ed signaling pathways are involved in cellular senescence, thus
sCLU might modulate (i.e., prevent) senescence by regulating the
activities of these receptors. It should be noted that knocking down
sCLU expression alone does not alter, or may enhance, IGF-1/
IGF-1R signaling [27].
Finally, our data strongly indicate that the remaining IGF-1/
IGF-1R signaling pathway, not affected by shRNA-sCLU specific
knockdown, but inhibited by IGF-1R receptor kinase-specific
agents (e.g., AG1024) are essential for the survival of senescent
cells and cause these cells to undergo programmed cell death
(Figure 4C). The potential significance of these differential
responses clinically could well depend on the age of a patient.
Since senescence is probably tumor-suppressive in young individ-
uals, but potentially tumor-promoting in aged individuals,
efficacious adjuvant treatment of patients using sCLU knockdown
therapies (using OGX011), or exposure to IGF-1R tyrosine kinase
inhibitors, may well depend on the overall age of the individual. In
the future, physicians may well decide to use OGX-011 in a young
patient to promote the tumor-suppressive properties of this
therapy to cause onset (and possibly increased overall numbers)
of senescence cells. Then, later in life and if IGF-1R inhibitors are
truly specific for senescent cells, the physician may subscribe such
inhibitors for prevention of senescence-induced microenviron-
mental changes that might promote tumor survival and progres-
sion. Further mechanism studies and trials in young and aged mice
in vivo will be required to explore these interesting senescence-
induced micro-environmental dynamics.
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